septerna - Search News

Order byBest matchMost fresh

News

Novo Nordisk Inks A Major Obesity Deal

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that could be worth up to $2.

Continue reading

· 6h · on MSN

· 4h · on MSN

Novo Nordisk, Septerna Agree $2.2 Billion Obesity Pill Deal

Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies

Novo Nordisk strikes deal with Septerna to develop obesity pills

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

Indianapolis Business Journal2h

Novo Nordisk inks $2.2B deal to develop weight-loss pill to rival Lilly’s orforglipron

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results